BUY Aurobindo PharmaSomil Mehta, Sharekhan

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))27 Jul 2026via Zee Business (Live)

Entry₹1,551Inferred
Target₹1,630
Total upside +5.09% (call closed)
Stop loss₹1,490-3.93% risk
Exit₹1,6306 Aug 2026, 9:15 am
Target hit+5.09%0.00%upside left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 6 Aug 2026
10 supporting5 neutral3 opposing
Supports the BUY call (10)

Aurobindo Pharma's Q1 Margin Story Improves; Macquarie Says Growth Picture Is Still Uneven

NewsNdtv-Profit·6 Aug · today

(opens in new tab)

Aurobindo Pharma Q1 Results: Profit, EBITDA beat estimates on strong global demand

NewsCnbc-Tv18·5 Aug · today

(opens in new tab)

Aurobindo Pharma Q1 Results: Profit Jumps 25%, Revenue Rises To Rs 9,150 Crore; Margins Improve

NewsNdtv-Profit·5 Aug · today

(opens in new tab)

2 advisors have active intraday BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·6 Aug · today

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·5 Aug · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.